Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.

http://www.wikidata.org/entity/Q44457719

about

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.Individualization of antiretroviral therapy.Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers Factors influencing lopinavir and atazanavir plasma concentration.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Pharmacogenetics of antiretroviral therapy.Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.

P2860

Q28546430-819A8134-CE64-457E-A4FC-BB36C7132FEB Q33787957-A943E646-D0DA-4F24-BEF4-6FE86ED69E62 Q34309475-6BCB4B01-D1ED-416E-8B78-8F3C5A95907C Q35079510-67B5A0C2-618E-45CB-BDE4-4A7FA32EE1B8 Q35629777-F6DEA159-33EF-4893-A5A5-970C410C0142 Q36441423-38F80705-00E0-47C4-BCD2-F1E780E238F0 Q36505387-D15A5D02-1134-49F6-8762-350ACD388317 Q36675895-32B002F9-E5F0-4637-A5D4-C8B223F912FC Q36905884-7EDF192F-4564-4F6D-96F2-09F68C843813 Q37187471-C2FB5CD8-64B2-401F-9FC0-AC03877B631F Q37476403-9360C633-DFB2-45E7-A443-ADE33639D7E5 Q37611687-1C0EF07B-4783-43FB-A391-D77B7D967A2B Q37866298-7459A888-6473-4D83-B76D-613BAE5D13C2 Q38221179-81249DCD-ADB1-4AD8-8F1B-597F366B0996 Q40603398-ED9736FA-CB6D-4243-BEAB-319B2C879A85 Q42263920-615015D4-7FC9-4040-AF24-342CE01FD673 Q43654216-C2522436-D1B5-417C-93B3-7D05EDB06770 Q43699242-410221A0-B370-4698-ACAF-9361B0E39DD3

P2860

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.

http://www.wikidata.org/entity/Q44457719

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Population pharmacokinetics of ...... iency virus-infected patients.

@en

Population pharmacokinetics of ...... iency virus-infected patients.

@nl

type

label

Population pharmacokinetics of ...... iency virus-infected patients.

@en

Population pharmacokinetics of ...... iency virus-infected patients.

@nl

prefLabel

Population pharmacokinetics of ...... iency virus-infected patients.

@en

Population pharmacokinetics of ...... iency virus-infected patients.

@nl

P1433

Q44457719-AD3DD144-214C-40E6-B416-4FFEB9C1FE64

P1476

Q44457719-DF2A7CFB-2BAB-46DC-A44E-B67DA7CFF3E8

P2093

Q44457719-081CB589-DB46-4CEB-9F8A-B0AEE7C05E4F

Q44457719-0AC6404E-7CC2-42F4-B187-32C178E70609

Q44457719-38EB26C8-76AD-43AA-A087-0135F84BDA5E

Q44457719-551406AE-0D78-46A6-901E-DEBDF5C0A601

Q44457719-7DAEFBAE-E693-4063-BCD9-9028FB27D98C

Q44457719-C1F9C0C5-59B4-42BF-B16C-8DEE89574835

Q44457719-D253564A-DA94-42D1-A44E-79E28D2FF085

Q44457719-E83F8BE7-8475-4B57-9F7B-8F762CD77075

P304

Q44457719-6F2DBB82-1E68-406C-96D3-ACA49EB23260

P31

Q44457719-61651553-77E5-4B1E-B03C-2053F7DAE07C

P356

Q44457719-E63B4DA8-EB19-4C3C-9483-4D7D10CE5D41

P433

Q44457719-D3408787-EF76-493B-B0CC-0A21796BA181

P478

Q44457719-AC9B0877-2537-433E-A8FD-90006505D7F1

P577

Q44457719-D62EB7A1-175E-441E-93B1-E8B6E4802B65

P698

Q44457719-8367A29D-0427-48BE-9CBC-BBA065CB1843

P356

FTD.0B013E3181897BFF

P1433

Therapeutic Drug Monitoring

P1476

Population pharmacokinetics of ...... iency virus-infected patients.

@en

P2093

Alain Lafeuillade

http://www.w3.org/2001/XMLSchema#string

Bruno Lacarelle

http://www.w3.org/2001/XMLSchema#string

Caroline Solas

http://www.w3.org/2001/XMLSchema#string

Isabelle Ravaux

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Gagnieu

http://www.w3.org/2001/XMLSchema#string

Marie-Pierre Drogoul

http://www.w3.org/2001/XMLSchema#string

Nicolas Simon

http://www.w3.org/2001/XMLSchema#string

Saadia Mokhtari

http://www.w3.org/2001/XMLSchema#string

P304

670-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FTD.0B013E3181897BFF

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18806695

http://www.w3.org/2001/XMLSchema#string